10% Free customization
The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032, witnessing a CAGR of 20.30% during the forecast period 2023-2032. The Europe EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine. This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Market introduction
The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease. The field of healthcare diagnostics has been revolutionized by its non-invasiveness, real-time monitoring capabilities, and potential for early disease diagnosis. EV-based liquid biopsy has improved patient outcomes, decreased expenses associated with healthcare, and provided a less intrusive and more accessible means of monitoring and diagnosing diseases, including cancer. Furthermore, the market expansion is anticipated to be aided by the entry of many established companies, including Bio-Techne Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.In addition, the market expansion for EV-based liquid biopsies has created economic opportunities, prompted industrial participants to collaborate with academic institutions, and sparked research and development efforts.
Market Segmentation
Segmentation 1: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe"
How can this report add value to an organization?
Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.Some of the prominent names in this market are:
- Abcam plc
- Qiagen N.V.
- Malvern Panalytical Ltd
- Lonza Group AG
This product will be delivered within 3-5 business days.
Table of Contents
1 Definition
2 Research Scope
3 Research Methodology
4 Markets Overview
5 Methods of EV Isolation and Analysis
6 Industry Insights
7 Market Dynamics
8 EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
9 Company Profiles
List of Figures
List of Tables
Executive Summary
The Europe EV-based liquid biopsy market is estimated to reach $115.34 million by 2032, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 20.30% during the forecast period 2023-2032.The Europe EV-Based Liquid Biopsy Market: Drivers and Challenges
Market Drivers
- Increase in geriatric population
- Rise in government funding and support
- Growing awareness related to cancer
Market Restraints
- Bio-ethical and legal constraints pertaining to protection of patient's genetic information
USPs of report
Market share analysis (by company) is provided.
- Analysis of business drivers and challenges of the Europe EV-Based Liquid Biopsy Market
- Detailed analysis of EV-Based Liquid Biopsy Market for Germany, France, Italy, Spain, and U.K.
Analyst’s Perspective on EV-Based Liquid Biopsy Market
The Principal Analyst states, 'The EV-based liquid biopsy market is experiencing rapid growth due to the use of EV-based liquid biopsy in both clinical and research settings, primarily focused on detecting and monitoring prostate, pancreatic, ovarian, lung, and bladder cancers. Further, the amplified funding and dedicated research efforts in EV-based liquid biopsy market is a major driver of market growth. In recent years, there has been a significant increase in the amount of funding being directed toward EV-based liquid biopsy research. This is due to the growing recognition of the potential of EVs to revolutionize cancer diagnostics. Therefore, the impact of the aforementioned factors is expected to drive the EV-based liquid biopsy market in the near future.'Some of the prominent names in this market are:
- Abcam plc
- Qiagen N.V.
- Malvern Panalytical Ltd
- Lonza Group AG
Key Questions Answered in the Report
- What is EV-based liquid biopsy?
- What is the market size and future potential of Europe EV-based liquid biopsy?
- What are the major market drivers, challenges, and opportunities and their respective impacts in the Europe EV-based liquid biopsy market?
- What are the key development strategies that have been implemented by the major players in order to sustain the competitive market?
Companies Mentioned
- Abcam plc
- Qiagen N.V.
- Malvern Panalytical Ltd
- Lonza Group AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 82 |
| Published | December 2023 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 21.85 Million |
| Forecasted Market Value ( USD | $ 115.34 Million |
| Compound Annual Growth Rate | 20.3% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 4 |
